Literature DB >> 8088411

A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin.

A Hongo1, S Seki, K Akiyama, T Kudo.   

Abstract

DNA damage induced by carboplatin [cis-diammine-(1, 1-cyclobutanedicarboxylato)platinum(II)] was studied in vitro in comparison with cisplatin [cis-diammine-dichloroplatinum(II)]. The drug-induced DNA damage monitored by conformational change of pUC18 plasmid DNA showed that carboplatin required 10 times higher drug concentration and 7.5 times longer incubation time than those of cisplatin to induce the same degree of conformational change on plasmid DNA. The carboplatin-induced DNA damage was promoted by the increase of pH of the reaction mixture for platinum-DNA adduct formation. Sequence gel analysis of carboplatin-damaged DNA indicated that carboplatin attacked preferentially the sequence of GG >> AG > GA > GNG in the order, similarly to the case of cisplatin. DNA adducts formed by carboplatin were analyzed by HPLC after a sequential digestion of carboplatin-treated DNA with deoxyribonuclease I and S1 nuclease. A single peak having the same retention time as that of bifunctional adduct of (dGMP)2Pt(NH3)2 appeared by treating DNA with carboplatin. The adduct was assigned to be d(pGpG) > Pt(NH3)2. These results suggested that carboplatin induces the same platinum-DNA adducts as those induced by cisplatin, and that the difference in efficiency or kinetics of DNA damage between carboplatin and cisplatin is due to difference of aquation rate between them.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8088411     DOI: 10.1016/0020-711x(94)90072-8

Source DB:  PubMed          Journal:  Int J Biochem        ISSN: 0020-711X


  12 in total

1.  Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA.

Authors:  C Kloft; C Eickhoff; K Schulze-Forster; H R Maurer; W Schunack; U Jaehde
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy.

Authors:  Abhimanyu Paraskar; Shivani Soni; Sudipta Basu; Chitra J Amarasiriwardena; Nicola Lupoli; Shyam Srivats; Rituparna Sinha Roy; Shiladitya Sengupta
Journal:  Nanotechnology       Date:  2011-05-17       Impact factor: 3.874

3.  Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy.

Authors:  Abhimanyu S Paraskar; Shivani Soni; Kenneth T Chin; Padmaparna Chaudhuri; Katherine W Muto; Julia Berkowitz; Michael W Handlogten; Nathan J Alves; Basar Bilgicer; Daniela M Dinulescu; Raghunath A Mashelkar; Shiladitya Sengupta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-23       Impact factor: 11.205

4.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.

Authors:  Q He; C H Liang; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

5.  Enhanced survival and cure of F98 glioma-bearing rats following intracerebral delivery of carboplatin in combination with photon irradiation.

Authors:  Julia Rousseau; Caroline Boudou; Rolf F Barth; Jacques Balosso; François Estève; Hélène Elleaume
Journal:  Clin Cancer Res       Date:  2007-08-28       Impact factor: 12.531

6.  Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer.

Authors:  Shruthi Sriramkumar; Timothy D Matthews; Ahmed H Ghobashi; Samuel A Miller; Pamela S VanderVere-Carozza; Katherine S Pawelczak; Kenneth P Nephew; John J Turchi; Heather M O'Hagan
Journal:  Mol Cancer Res       Date:  2020-08-14       Impact factor: 5.852

7.  Intracerebral delivery of carboplatin in combination with either 6 MV photons or monoenergetic synchrotron X-rays are equally efficacious for treatment of the F98 rat glioma.

Authors:  Laure Bobyk; Magali Edouard; Pierre Deman; Julia Rousseau; Jean-François Adam; Jean-Luc Ravanat; François Estève; Jacques Balosso; Rolf F Barth; Hélène Elleaume
Journal:  J Exp Clin Cancer Res       Date:  2012-09-20

8.  Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.

Authors:  Timothy O'Donnell; Elizabeth L Christie; Arun Ahuja; Jacqueline Buros; B Arman Aksoy; David D L Bowtell; Alexandra Snyder; Jeff Hammerbacher
Journal:  BMC Cancer       Date:  2018-01-22       Impact factor: 4.430

Review 9.  Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.

Authors:  Sara Bouberhan; Lauren Philp; Sarah Hill; Linah F Al-Alem; Bo Rueda
Journal:  Cancers (Basel)       Date:  2020-05-11       Impact factor: 6.639

10.  Comparative gonadotoxicity of the chemotherapy drugs cisplatin and carboplatin on prepubertal mouse gonads.

Authors:  Caroline M Allen; Federica Lopes; Rod T Mitchell; Norah Spears
Journal:  Mol Hum Reprod       Date:  2020-03-26       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.